PART I Overview Theravance Biopharma, Inc. (we, our, Theravance Biopharma or the Company) is a biopharmaceutical company primarily focused on the development and commercialization of medicines. Our focus is to deliver medicines that make a difference in peoples lives. In pursuit of our purpose, we leverage decades of expertise, which has led to the development of the United States (US) Food and Drug Administration (the FDA) approved YUPELRI (revefenacin) inhalation solution indicated for the mai...
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001104659-26-033077 | EDGAR | 69K words |
| 2025-03-07 | 2024-12-31 | 0001558370-25-002447 | EDGAR | — |
| 2024-03-01 | 2023-12-31 | 0001558370-24-002267 | EDGAR | — |
| 2023-03-01 | 2022-12-31 | 0001558370-23-002595 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001558370-22-002373 | EDGAR | — |
| 2021-02-26 | 2020-12-31 | 0001558370-21-002006 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001558370-20-001644 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001558370-19-001346 | EDGAR | — |
| 2018-02-28 | 2017-12-31 | 0001047469-18-001160 | EDGAR | — |
| 2017-03-01 | 2016-12-31 | 0001047469-17-001086 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-110382 | EDGAR | 46K words |
| 2025-08-13 | 2025-06-30 | 0001558370-25-011408 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001558370-25-007398 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001558370-24-015602 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011636 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001558370-24-008201 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001558370-23-018612 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001558370-23-014070 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001558370-23-008951 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001558370-22-017048 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001558370-22-012666 | EDGAR | — |
| 2022-05-06 | 2022-03-31 | 0001558370-22-007651 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001104659-26-036870 | EDGAR | 1K words |
| 2026-03-19 | 0001104659-26-031795 | EDGAR | — |
| 2026-03-03 | 0001104659-26-022572 | EDGAR | — |
| 2026-01-12 | 0001104659-26-002726 | EDGAR | — |
| 2025-12-08 | 0001104659-25-119032 | EDGAR | — |
| 2025-11-10 | 0001104659-25-109146 | EDGAR | — |
| 2025-08-25 | 0001104659-25-082048 | EDGAR | — |
| 2025-08-20 | 0001104659-25-080470 | EDGAR | — |
| 2025-08-12 | 0001104659-25-076837 | EDGAR | — |
| 2025-06-26 | 0001104659-25-062722 | EDGAR | — |
239 total filings indexed. 207 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001583107 |
| Ticker | TBPH |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | CA |
| Website | https://www.theravance.com |
| Listed | 2014-05-16 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report